Sareum’s small molecule drug discovery expertise builds value by developing drug candidates, focused on cancer and autoimmune disease, for licencing to pharmaceutical and biotechnology companies.
12 September 2022
28 July 2022
04 July 2022
TYK2/JAK1 inhibitor SDC-1801, targeting autoimmune diseases, is being prepared for first clinical studies in 2022
IMC SDC-1801 CTA submission, Aug 2022
BioTrinity, April 2022
IMC Half Year Results, Feb 2022
IMC Full Year Results, Oct 2021
Sareum Limited
Unit 2A, Langford Arch
London Road, Pampisford
Cambridge CB22 3FX
United Kingdom
tel: +44 (0) 1223 497700
fax: +44 (0) 1223 497701
